No description available.

Hemophilia B is a debilitating and life-threatening disorder caused by a deficiency in or dysfunction of factor IX (FIX), a complex plasma glycoprotein required for the formation and maintenance of blood clots. Treatment of hemophilia B involves infusion of replacement FIX currently derived from two sources: FIX purified from pools of human plasma (pd-FIX) and a single recombinant FIX product generated in genetically engineered Chinese hamster ovary (CHO) cells. Both of these FIX products are prohibitively expensive, limiting of the treatment options of hemophiliacs worldwide. As a result, a more abundant and affordable FIX product would greatly improve the life prospects for hemophiliacs. The biological activity of FIX is dependent upon its numerous post-translational modifications (PTMs), including gamma-carboxylation, proteolytic maturation, phosphorylation, sulfation, and glycosylation. Of these PTMs, those known to be vital for activity are gamma-carboxylation of multiple glutamate residues near the N-terminus and proteolytic cleavage of the FIX propeptide. When expressed at a high rate in exogenous expression systems, however, the ability of current systems to effect the necessary PTMs is severely rate limited, restricting the production of active FIX. The transgenic pig bioreactor represents a promising source for the production of large quantities biologically active FIX due to its demonstrated ability to perform the required FIX PTMs. It was the goal of this study to characterize the PTM structure and the resulting function of recombinant FIX when expressed at 1-3 mg/ml in the transgenic pig mammary epithelium (tg-FIX). It was found that the expressed tg-FIX is comprised of a heterogeneous mixture of FIX PTM isoforms. This mixture represents a spectrum of tg-FIX molecules of varying gamma-carboxyglutamic acid (Gla) and propeptide content, indicating that rate limitations in effecting these PTMs are present. A purification process was developed utilizing heparin-affinity chromatography to purify the total population of tg-FIX from pig milk, a complex multi-phase feedstock. Subsequently, a process was developed to fractionate the total population of tg-FIX into subpopulations based upon the extent of post-translational modification. Q ion-exchange chromatography was utilized to fractionate tg-FIX based upon molecular acidity which was found to be correlated to both biological activity and Gla content. The resulting biologically active tg-FIX population contained an average of 7 of the 12 Gla residues found in pd-FIX. Immuno-affinity chromatography was subsequently utilized to further fractionate tg-FIX into mature tg-FIX and propeptide-containing tg-FIX populations. The isolated FIX PTM populations were subjected to functional analysis by investigating in vitro clotting activity, activation by factor XIa, and in vivo pharmacokinetics. From this analysis it was found that mature tg-FIX with an average 7 Gla residues, representing approximately 9% of the total tg-FIX produced, exhibits wild-type in vitro clotting activity and normal activation by factor XIa. The remainder of the tg-FIX produced, characterized by either a lower Gla content or the presence of the propeptide, was found to be inactive and displayed less efficient activation by factor IXa. In an in vivo pharmacokinetic study in the hemophilia B mouse model, biologically active tg-FIX was found to possess altered circulating properties. Tg-FIX was characterized by a lower recovery, approximately one-sixth that of pd-FIX, but an extended circulation half-life. From this study it was found that the mean residence time of tg-FIX after injections is approximately twice that observed for pd-FIX. These altered pharmacokinetic properties are likely linked to the unique tg-FIX PTM structure, perhaps through altered endothelial cell binding characteristics caused by the reduced Gla content. / Ph. D.

L-asparaginase (EC 3.5.1.1), a therapeutic enzyme used in the treatment of childhood acute lymphoblastic leukemia (ALL). Hence, the goal of this work is study the expression and evaluation of hydrolysis activity of native sequence (X12746) encoding for L-asparaginase from Erwinia chrysanthemi NCPBB1125 in the popular expression system Pichia pastoris. The sequence of asn encoded for mature protein was expressed in P. pastoris SMD1168 and X33. SDS-PAGE analysis showed recombinant L-asparaginase was secreted efficiently. Stable and high hydrolysis activity of extracellular L-asparaginase in P. pastoris SMD1168 making it a potential candidate to produce recombinant protein. After purification, a specific band whose appearance approximately 45 kDa indicating the glycosylated protein with specific activity by 6.251 Umg-1 and about 3 folds purifications. / L-asparaginase (EC 3.5.1.1), một loại enzyme được sử dụng trong điều trị bệng ung thư bạch cầu mãn tính ở trẻ em. Mục tiêu của nghiên cứu này là biểu hiện và đánh giá hoạt tính thủy phân của L-asparaginase mã hóa bởi đoạn gene (X12746) tương ứng từ Erwinia chrysanthemi NCPBB1125 được biểu hiện trong nấm men Pichia pastoris. Gene đã được cắt signal peptide và biểu hiện trong P. pastoris SMD1168 and X33. Qua phân tích kết quả điện di SDS-PAGE của môi trường sau lên men, L-asparaginase tái tổ hợp được tìm thấy trong dịch ngoại bào của P. pastoris. Với khả năng sản xuất protein có hoạt tính cao hơn so với chủng P. pastoris X33, SMD1168 được lựa chọn để biểu hiện L-asparaginase tái tổ hợp. Sau khi tinh sạch, sự xuất hiện của một băng có kích khối lượng phân tử xấp xỉ 45 kDa trên điện di SDS-PAGE cho thấy protein tái tổ hợp đã bị glycosyl hóa với hoạt tính riêng 6.251 Umg-1 và đạt độ sạch 3.471 lần.

<p>The goal of this work was to contribute to the fed-batch process optimisation task by deriving parameters that have considerable impact on productivity as well as product quality The chosen parameters were I) the design of the glucose feed profile, II) the choice of induction strategy, with respect to the method of addition, and III) the time of the induction, with respect to the specific glucose consumption rate. </p><p>The present fed-batch experiments using the lacUV5-promoter, for production of b-galactosidase, have shown that a high glucose feed rate gives a specific production rate, q_p, that is twice as high, after induction, compared to a feed rate that is 2.5 times lower. The constant accumulation of lacZ-mRNA indicates that the translational capacity is initially limiting the synthesis machinery, but after four hours of maximum specific production and a corresponding drop in lacZ-mRNA production, the cultivation is likely to be transcription limited. The high feed-rate system resulted in high accumulation of β-galactosidase, corresponding to 40% of total cellular proteins.</p><p>By design of feed profiles in a fed-batch process the detrimental effects of overflow metabolism, giving acetic acid formation, can be avoided. However, the results show that a one-dose addition of isopropyl-β-D-galactopyranoside (IPTG), provokes a non-growth associated production of acetic acid. This response can be alleviated by; lowering the inducer concentration (in this case to below 165 μM), by further reducing the feed rate of glucose or by using alternative induction methods. The use of a stepwise addition or a feed of IPTG thus delayed and reduced the level of acetic acid accumulation. It was also shown that a small change in the time-point of induction lead to large variability, regarding both productivity and acetic acid accumulation, in a fed-batch cultivation, </p><p>In order to further investigate the protein quality two additional proteins were studied in fed-batch cultivations using high and low glucose feed. The aim was to prove the hypothesis that the feed related change in the rate of synthesis of the nascent polypeptide controls the product quality. For the two proteins: Zb-MalE (wt) and Zb-MalE31 (mutant), the transcription rate, in terms of amount of IPTG, and translation rate, in terms of changes in feed rate, influences the percentage of inclusion body formation and degradation of nascent polypeptide. The data show a higher rate of inclusion body formation for the model protein Zb-MalE31 during high feed rate cultivations, as well as at high levels of inducer. Furthermore, the rate of proteolysis was significantly higher for a high feed rate. The high feed rate thus results in a higher rate of synthesis but a lower corresponding quality, for the model proteins studied.</p><p>In the present investigation of fed-batch cultivations using several different expression vectors, it was found that the central alarmone guanosine tetraphosphate (ppGpp) was formed at both high and low feed rates upon induction. It could be shown, however, that by secretion of Zb-MalE to the periplasm, the stringent response could be avoided. This might be due to the decreased burden on the host where the secretion of product further seems to make the cell able to redirect the carbon flux from overflow metabolism, since no acetic acid was produced. The secretion also demonstrates that the growth arrest could be aborted, which is otherwise gained in the P_malKproduction system.</p><p>A novel fed-batch process based on the promoters for the universal stress proteins A and B (P_uspA, P_uspB) was designed to make use of these powerful promoters in an industrial production context. It was concluded that the process had to start from a high specific growth rate and induction was performed once a limiting feed started. This was done to purposely induce the stringent response and/or acetic acid accumulation since this was required for induction. In the suggested system, induction has to be performed and maintained at continuous substrate feeding, whilst avoiding exceeding the cellular capacity, since the stationary phase starvation alone did not lead to production. In conclusion, a new stress induction based production system was achieved resulting in high accumulations of product protein without any detected metabolic side effects.</p>

African horsesickness (AHS) is one of the most deadly diseases of horses, with a mortality rate of over 90% in horses that have not been exposed to any African horsesickness virus (AHSV) serotype previously (Howell, 1960; Darpel et al., 2011). The Orbiviruses, African horsesickness virus (AHSV) and Bluetongue virus (BTV), are primarily transmitted to their mammalian hosts through certain haematophagous midge vectors (Culicoides spp.) (Erasmus, 1973). The selective cleavage of BTV and AHSV VP2 by trypsin-like serine proteases (Marchi et al., 1995) resulted in the generation of subsequent infectious sub-viral particles (ISVP) (Marchi et al., 1995; van Dijk & Huismans, 1982). It is believed that this cleavage affects the ability of the virus to infect cells of the mammalian and vector host (Darpel et al., 2011). Darpel et al (2011) identified a trypsinlike serine protease in the saliva of Culicoides sonorensis (C. sonorensis), which also cleaves the serotype determinant viral protein 2 (VP2) of BTV. And, a similar cleavage pattern was also observed by van Dijk & Huismans (1982) and Marchi et al (1995) with the use of trypsin and chymotrypsin. Manole et al (2012) recently determined the structure of a naturally occurring African horsesickness virus serotype 7 (AHSV7) strain with a truncated VP2. Upon further investigation, this strain was also shown to be more infective than the AHSV4 HS32/62 strain, since it outgrew AHSV4 in culture (Manole et al., 2012). Therefore, through proteolytic cleavage of these viral particles, the ability of the adult Culicoides to transmit the virus might be significantly increased (Dimmock, 1982; Darpel et al., 2011). Based on these findings, it is important to investigate the factors that influence the capability of arthropod-borne viruses to infect their insect vectors, mammalian hosts and their known reservoirs. In this study, we postulated that one of the vectors for AHSV, Culicoides imicola (C. imicola), has a protease similar to the 29 kDa C. sonorensis trypsin-like serine protease identified by Darpel et al (2011). Proteins in the total homogenate of C. imicola were separated on SDS-PAGE and yielded several protein bands, one of which also had a molecular mass of around 29 kDa. Furthermore, proteolytic activity was observed on a gelatin-based sodium dodecyl sulfate polyacryamide gel electrophoresis (SDS-PAGE) gel. The activity of the protein of interest was also confirmed to be a trypsin-like serine protease with the use of class-specific protease inhibitors. A recombinant trypsin-like serine protease of C. sonorensis was generated using the pColdIII bacterial expression vector. The expressed protein was partially purified with nickel ion affinity chromatography. Zymography also confirmed proteolytic activity. With the use of the protease substrates containing fluorescent tags and class specific protease inhibitors, the expressed protein was classified as a serine protease. It was also proposed that incubation of purified AHSV4 with the recombinant protease would result in the cleavage of AHSV4 VP2, resulting in similar VP2 digestion patterns as observed in BTV by Darpel et al (2011) or the truncated VP2 of AHSV7 by Manole et al (2012). BHK-21 cell cultured AHSV4 was partially purified through Caesium chloride gradient ultracentrifugation after which the virus was incubated with the recombinant protease. Since not enough virus sample was obtained, the outcome of VP2 digestion was undetermined. In the last part of this study, it was postulated that C. imicola and C. sonorensis have the same trypsin-like serine protease responsible for the cleavage of VP2 based on the protease activity visualised in the whole midge homogenate. Since the genome of C. imicola is not yet sequenced, the sequence of this likely protease is still unknown. Therefore, we attempted to identify this C. imicola protease through polymerase chain reaction (PCR) amplification. Total isolated ribonucleic acid (RNA) of C. imicola was used to synthesize complementary deoxyribonucleic acid (cDNA). The cDNA was subjected to PCR using C. sonorensis trypsin-like serine protease-based primers. An 830 bp DNA fragment was amplified. However, sequence alignment and the basic local alignment software tool (BLAST), revealed that DNA did not encode with any other known proteins or proteases. From the literature it seems that there is a correlation between the proteases in the vector and the mammalian species that succumb to AHS (Darpel et al., 2011, Wilson et al., 2009, Marchi et al., 1995). Based on the work performed in the study, a proteolytically active protein similar to the 29 kDa protein of C. sonorensis is present in C. imicola. The 29 kDa protease of C. sonorensis can also be expressed in bacteria which could aid in future investigations on how proteolytic viral modifications affect infectivity between different host species. / MSc (Biochemistry), North-West University, Potchefstroom Campus, 2014

O Plasmodium vivax é a espécie causadora de malária de maior distribuição mundial e maior prevalência nas Américas. A complexidade do ciclo de vida do parasito e sua extensa diversidade antigênica têm dificultado a obtenção de uma vacina eficaz e inferem que seja pouco provável que este objetivo seja alcançado utilizando um único antígeno. Neste contexto, a combinação de regiões imunodominantes de antígenos de um ou mais estágios do ciclo de vida do Plasmodium pode ser uma estratégia com melhor prognóstico na indução de resposta imune protetora e duradoura contra a atividade parasitária. Este trabalho avaliou a imunogenicidade, em camundongos, de uma formulação vacinal composta pela mistura dos antígenos CSP, pré-eritrocítico e AMA-1, o qual é expresso em ambos os estágios, préeritrocítico e eritrocítico assexuado. A proteína quimérica yPvCSAllFL, que contém epítopos para células B da região central (repeats) das 3 variantes alélicas PvCSP-VK210, PvCSP-VK247 e PvCSP-P. vivax-like fusionados, e a yPvAMA-1 foram expressas com sucesso em leveduras Pichia pastoris e purificadas por métodos cromatográficos para a imunização de camundongos BALB/c e C57BL/6, na presença do adjuvante Poly(I:C), agonista de TLR3. Por ELISA, foram determinados os títulos de anticorpos, as subclasses de IgG e a avidez destes pelas proteínas indutoras, administradas isoladamente ou em combinação. A resposta de anticorpos anti-yPvCSAllFL mostrou ser linhagem dependente, tendo sido observado altos títulos de anticorpos IgG (106) em C57BL/6, os quais se mantiveram elevados por até 6 meses após a última dose. Os anticorpos anti-yPvCSAllFL, predominantemente IgG1, foram capazes de reconhecer proteínas representando as 3 variantes alélicas. No geral, a coadministração dos antígenos yPvCSAllFL e yPvAMA-1 não comprometeu a resposta de anticorpos individual. Utilizando este protocolo de vacinação não foi possível detectar resposta proliferativa de células TCD3+TCD4+ ou TCD3+TCD8+ específicas após a estimulação com yPvCSAllFL. Os índices de proliferação (8,31%) e o padrão de secreção das citocinas IFN-&#947;, IL-2, TNF-&#945; e IL-10, associados à yPvAMA-1, sofreram redução com a coadministração de antígenos (6,33%) e alteração, com elevação de IL-2 em detrimento das demais citocinas. Os dados gerados no estudo das formulações vacinais apresentadas neste trabalho podem ser úteis para o desenvolvimento de uma vacina anti-P. vivax, principalmente por explorarem estratégias de combinação e fusão de antígenos. / Plasmodium vivax is the species of malaria more widely distributed worldwide and with higher prevalence in the Americas. The complexity of the parasite life cycle and its extensive antigenic diversity have hampered the achievement of an effective vaccine and infer that it is unlikely that this goal will be achieved using a single antigen. In this context, the combination of immunodominant regions of antigens of one or more stages of the Plasmodium life cycle can be a strategy with better prognosis at inducing protective and durable immune responses against this parasite. Our study assessed the immunogenicity of vaccine formulations consisting of mixture of antigens CSP, pre-erythrocytic and AMA-1, which is expressed in the both stages, pre-erythrocytic and erythrocytic asexual, in mice. The chimeric protein yPvCSAllFL, which contains B-cell epitopes of the central region (repeats) of the 3 allelic variants PvCSP-VK210, PvCSP-VK247 and PvCSP-P. vivax-like fused, and the yPvAMA-1 were successfully expressed in the yeast Pichia pastoris and purified by chromatographic methods for immunization of BALB/c and C57BL/6 mice in the presence of the adjuvant Poly(I:C), a TLR3 agonist. By ELISA, we determined the titles, IgG subclasses and the avidity of the antibodies to these proteins, administered alone or in combination. The immune response to yPvCSAllFL proved to be dependent on mouse strain, having been observed high titers of IgG antibodies (106) in C57BL/6, which remained high for up to 6 months after the last dose. Anti-yPvCSAllFL antibodies, predominantly IgG1, were able to recognize proteins representing the 3 allelic variants. In general, the co-administration of yPvCSAllFL and yPvAMA-1 antigens did not compromise the individual antibodies response. Using this vaccination protocol, we could not detect cell specific proliferative responses of TCD3+TCD4+ or TCD3+TCD8+ after stimulation with yPvCSAllFL. The proliferation (8.31%) and the pattern of secretion of cytokines IFN-&#947;, IL-2, TNF-&#945; and IL-10, associated with the yPvAMA-1, were reduced during the co-administration (6.33%) and compensated by the elevation of IL-2. The data generated on the study of vaccine formulations presented in this thesis may be useful for the development of a vaccine anti-P. vivax, mainly by exploiting strategies of combination and fusion of antigens.

A agalaxia contagiosa é uma doença de notificação obrigatória que causa severas perdas econômicas para produção de ovinos e caprinos mundialmente. Apesar de seu impacto na produção animal, pouco se sabe sobre os fatores de virulência e patogenicidade do M. agalactiae (principal agente etiológico). Desta maneira, o presente estudo possuiu como objetivo a identificação, purificação e caracterização de proteínas antigênicas de M. agalactiae. Para tanto, quatro proteínas de superfície com potencial antigênico (WP_011949419.1, WP_011949418.1 (P40), WP_011949336.1, WP_011949770.1) foram selecionadas. Essas proteínas foram expressas em Escherichia coli e purificadas em coluna de níquel. As proteínas purificadas foram avaliadas quanto a antigenicidade em Western blotting utilizando soros de caprinos naturalmente infectados com M. agalactiae. Todas as proteínas expressas foram imunorreativas aos soros de caprinos naturalmente infectados, demonstrando que as proteínas utilizadas nesse estudo são possivelmente antigênicas e possuem epítopos acessíveis. / The Contagious agalactia is a notifiable disease that causes severe economic losses to sheep and goats worldwide. Despite its impact on animal production, little is known about the virulence factors and pathogenicity of M. agalactiae (main etiological agent). Thus, the present study identified, purified and characterized antigenic proteins of M. agalactiae. Therefore, four surface proteins with antigenic potential (WP_011949419.1, WP_011949418.1 (P40), WP_011949336.1, WP_011949770.1) were selected. These proteins were expressed in Escherichia coli and purified on nickel column. The purified proteins were assayed for antigenicity by Western blotting using goat sera naturally infected with M. agalactiae. All expressed proteins were immunoreactive with sera from naturally infected goats, demonstrating that the proteins used in this study are possibly antigenics and it have acessible epitopes.

As bactérias patogênicas do gênero Leptospira são o agente causador da leptospirose, uma doença de importância global. As leptospiras patogênicas causam infecção em um amplo espectro de animais e no homem. As leptospiras podem invadir o corpo humano através de abrasões na pele e mucosa. A invasividade bacteriana depende de várias etapas, tais como: aderência, invasão e disseminação através dos tecidos do hospedeiro. Recentemente, nosso grupo identificou proteínas de membrana externa que atuam como adesinas de leptospira e/ou receptores de componentes do plasma hospedeiro, o que poderia contribuir para a patogenicidade bacteriana. Assim, o presente projeto tem como objetivo avaliar as propriedades funcionais do gene LIC10920, identificado na sequência genômica de Leptospira interrogans sorovar Copenhageni, como uma proteína hipotética, predita de membrana externa. A sequência LIC10920 foi amplificada por PCR e clonada no vetor de expressão pAE. O plasmídeo pAE contendo o inserto foi introduzido em estirpes de E. coli para a expressão da proteína. A proteína recombinante rLIC10920 foi purificada por cromatografia de afinidade a níquel e sua integridade estrutural foi avaliada pela técnica de dicroísmo circular. Camundongos foram imunizados com a LIC10920 para a avaliação da sua imunogenicidade. A presença de IgG humano contra LIC10920, foi avaliada por ELISA, em amostras de soro de pacientes com leptospirose. Assim, como a sua ligação com componentes da matriz extracelular e plasma do hospedeiro. Animais imunizados apresentaram alto título de anticorpos contra LIC10920. Além disso, a proteína foi reconhecida por anticorpos presente em amostras de soro humano infectado. A proteína foi capaz de interagir com plasminogênio e laminina de maneira dose-dependente e saturável. Em ambas as interações, a participação das regiões imunogênicas se mostrou importante. rLIC10920 foi capaz de capturar o plasminogênio direto do soro humano também de maneira dose-dependente. Por fim, foi observado que o plasminogênio ligado a rLIC10920 pode ser convertido em plasmina. A proteína em estudo é expressa durante a infecção e podemos atribuir a função de adesina, com papel na patogênese da bactéria. / Pathogenic bacteria of genus Leptospira are the causative agent of leptospirosis, a disease of global importance. Pathogenic leptospires cause infection in a broad spectrum of animals and humans. Pathogenic leptospires can efficiently invade the human body through skin and mucosa and promptly spread into blood vessels, reaching target organs. Bacterial invasiveness depends on several steps, such as adherence, invasion and throughout host tissues. Recently, our group has identified outer membrane proteins that act as leptospiral adhesins and/or receptors of host plasma components, which could contribute for bacterial pathogenesis. This project aims to evaluate the functional properties of the gene LIC10920, identified in the genome sequence of Leptospira interrogans serovar Copenhageni, as a predicted outer membrane protein of unknown function. The LIC10920 sequence was amplified by PCR, cloned into the expression vector pAE. Plasmids containing cloned DNA were introduced in E. coli strains for protein expression. The recombinant protein was purified by the metal affinity chromatography and its structural integrity was assessed by circular dichroism spectroscopy. Mice were subcutaneously immunized with LIC10920 for immunogenicity evaluation. The presence of IgG against LIC10920 in confirmed leptospirosis human serum samples was evaluated by ELISA. Binding of protein with extracellular matrix or plasma components was also assessed. Sera from immunized animals show that the rLIC10920 protein is capable to stimulate antibody immune response in mice. In addition, the protein is recognized by antibodies in leptospirosis human serum samples. The recombinant protein was capable of binding plasminogen and laminin. Dose-dependent and saturable binding was observed when increasing concentrations of the rLIC10920 were allowed adhere to a fixed concentration of plasminogen or of laminin, fulfilling the receptor-ligand interactions. In both cases, the participation of the immunogenic regions occurs, but in the case of laminin, the dependence is greater with structured epitopes. It has been shown that plasminogen linked to rLIC10920 can be converted to plasmin in the presence of activator. The recombinant protein was able to capture the plasminogen directly from normal human serum in a dose-dependent manner, suggesting the involvement of native protein in host-pathogen interactions. The protein under study is expressed during the infection and due to its capacity of interaction with host components, we may anticipate its role in leptospiral pathogenesis.

O P. vivax é a segunda espécie mais prevalente causadora de malária no mundo. Medidas de controle ineficientes exigem o desenvolvimento de novas estratégias de prevenção, como vacinas, novas drogas e novos inseticidas. O objetivo geral do trabalho foi gerar uma formulação vacinal universal com proteínas e adenovírus recombinantes capazes de induzir anticorpos contra as diferentes formas alélicas da proteína circumsporozoíta (CSP) do P. vivax. As proteínas foram produzidas em E. coli e purificadas por cromatografia de afinidade e troca iônica. A obtenção destas proteínas nos permitiu testar qual seria a melhor formulação vacinal para a indução de anticorpos contra as três formas alélicas da proteína CSP de P. vivax (PvCSP). Anticorpos específicos reconheceram esporozoítas do P. vivax por imunofluorescência. Por fim testamos o uso de dois adenovírus recombinantes, um símio e um humano, deficientes em replicação, expressando as três regiões imunodominantes da proteína PvCSP em fusão. Estes foram capazes de induzir resposta imune específica contra as proteínas PvCSP sendo testados em esquema de prime-boost heterólogo, onde camundongos foram primados com os adenovírus e nas doses-reforço receberam a mistura com as três proteínas recombinantes. / The Plasmodium vivax is the second most prevalent species of malaria in the world. Inefficient measures of control used today demand the development of new strategies for prevention, as vaccines, new drugs and new insecticides. The central objective of this thesis was to generate a universal vaccine formulation with proteins and recombinant adenoviral vectors representing the different allelic forms of the circumsporozoite protein (CSP) of the P. vivax. The recombinant proteins were expressed in E. coli and purified. These proteins allowed us to test which would be the best vaccine formulation for the induction of antibodies against the three allelic forms of CSP. The specific antibodies also recognized P. vivax sporozoites by immunofluorescence. Finally we test the use of two recombinant adenoviral vectors, a simian and a human, both replication deficient, expressing a protein containing the repeat regions of the CSP in fusion. These adenoviral vectors induced specific immune response against CSP and were successfully used in an immunization regimen of heterologous prime and boost where in the first dose the mice received recombinant adenoviral vector and in the subsequent doses, the mixture with three recombinant proteins.

A agalaxia contagiosa é uma doença de notificação obrigatória que causa severas perdas econômicas para produção de ovinos e caprinos mundialmente. Apesar de seu impacto na produção animal, pouco se sabe sobre os fatores de virulência e patogenicidade do M. agalactiae (principal agente etiológico). Desta maneira, o presente estudo possuiu como objetivo a identificação, purificação e caracterização de proteínas antigênicas de M. agalactiae. Para tanto, quatro proteínas de superfície com potencial antigênico (WP_011949419.1, WP_011949418.1 (P40), WP_011949336.1, WP_011949770.1) foram selecionadas. Essas proteínas foram expressas em Escherichia coli e purificadas em coluna de níquel. As proteínas purificadas foram avaliadas quanto a antigenicidade em Western blotting utilizando soros de caprinos naturalmente infectados com M. agalactiae. Todas as proteínas expressas foram imunorreativas aos soros de caprinos naturalmente infectados, demonstrando que as proteínas utilizadas nesse estudo são possivelmente antigênicas e possuem epítopos acessíveis. / The Contagious agalactia is a notifiable disease that causes severe economic losses to sheep and goats worldwide. Despite its impact on animal production, little is known about the virulence factors and pathogenicity of M. agalactiae (main etiological agent). Thus, the present study identified, purified and characterized antigenic proteins of M. agalactiae. Therefore, four surface proteins with antigenic potential (WP_011949419.1, WP_011949418.1 (P40), WP_011949336.1, WP_011949770.1) were selected. These proteins were expressed in Escherichia coli and purified on nickel column. The purified proteins were assayed for antigenicity by Western blotting using goat sera naturally infected with M. agalactiae. All expressed proteins were immunoreactive with sera from naturally infected goats, demonstrating that the proteins used in this study are possibly antigenics and it have acessible epitopes.